Advertisement
UK markets close in 1 hour 57 minutes
  • FTSE 100

    8,075.46
    +30.65 (+0.38%)
     
  • FTSE 250

    19,768.07
    -31.65 (-0.16%)
     
  • AIM

    755.09
    +0.22 (+0.03%)
     
  • GBP/EUR

    1.1641
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.2453
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    52,996.20
    -109.55 (-0.21%)
     
  • CMC Crypto 200

    1,429.24
    +5.14 (+0.36%)
     
  • S&P 500

    5,076.75
    +6.20 (+0.12%)
     
  • DOW

    38,453.76
    -49.93 (-0.13%)
     
  • CRUDE OIL

    82.93
    -0.43 (-0.52%)
     
  • GOLD FUTURES

    2,334.50
    -7.60 (-0.32%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • DAX

    18,135.09
    -2.56 (-0.01%)
     
  • CAC 40

    8,128.01
    +22.23 (+0.27%)
     

Amgen's Just-Approved Migraine Drug Will Cost $6,900 a Year

Amgen's Just-Approved Migraine Drug Will Cost $6,900 a Year

Amgen Inc. will charge a lower-than-expected $6,900 a year for a novel migraine treatment that investors hope will become the biotechnology giant’s next blockbuster. The Food and Drug Administration approved the drug, which will be marketed under the brand name Aimovig, on Thursday. Amgen’s pricing plans for Aimovig have been closely watched amid a wider U.S. debate over high prescription costs.